Patents by Inventor Zhi-yong Yang

Zhi-yong Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170320967
    Abstract: The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.
    Type: Application
    Filed: April 13, 2017
    Publication date: November 9, 2017
    Inventors: Zhi-Yong YANG, Gary J. NABEL, Lan WU, Edward SEUNG, Ronnie WEI, Jochen BENINGA, Ercole RAO, Wulf Dirk LEUSCHNER, Christian BEIL, Christian LANGE, Carsten CORVEY
  • Patent number: 9796774
    Abstract: The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: October 24, 2017
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: John Mascola, Dennis R. Burton, Wayne Koff, Peter Kwong, Gary Nabel, Sanjay K. Phogat, Pascal Raymond Georges Poignard, Melissa Danielle De Jean St. Marcel Simek-Lemos, Xueling Wu, Tongqing Zhou, Zhi-Yong Yang
  • Publication number: 20170267748
    Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 21, 2017
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
  • Patent number: 9738703
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: August 22, 2017
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Washington
    Inventors: John Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, William Schief
  • Patent number: 9695230
    Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: July 4, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
  • Publication number: 20160289305
    Abstract: The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.
    Type: Application
    Filed: April 19, 2016
    Publication date: October 6, 2016
    Inventors: John Mascola, Dennis R. Burton, Wayne Koff, Peter Kwong, Gary Nabel, Sanjay K. Phogat, Pascal Raymond Georges Poignard, Melissa Danielle De Jean St. Marcel Simek-Lemos, Xueling Wu, Tongqing Zhou, Zhi-Yong Yang
  • Patent number: 9382311
    Abstract: The present application relates broadly neutralizing monoclonal antibodies directed against HIV-1. In particular, monoclonal antibodies VRC-PG04 and VRC-PG05 are disclosed.
    Type: Grant
    Filed: March 10, 2013
    Date of Patent: July 5, 2016
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: John Mascola, Dennis R. Burton, Wayne Koff, Peter Kwong, Gary Nabel, Sanjay K. Phogat, Pascal Raymond Georges Poignard, Melissa Danielle De Jean St. Marcel Simek-Lemos, Xueling Wu, Tongqing Zhou, Zhi-Yong Yang
  • Publication number: 20160009789
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
    Type: Application
    Filed: September 24, 2015
    Publication date: January 14, 2016
    Applicants: UNIVERSITY OF WASHINGTON, The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: John Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, William Schief
  • Patent number: 9175070
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: November 3, 2015
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Washington
    Inventors: John R. Mascola, Richard T. Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary J. Nabel, Peter D. Kwong, Tongqing Zhou, Mark Connors, William R. Schief
  • Patent number: 9012618
    Abstract: The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: April 21, 2015
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Nancy Sullivan, Bimal Chakrabarti, Zhi-Yong Yang, Maria Grazia Pau, Jaap Goudsmit, Gary Nabel
  • Publication number: 20140322163
    Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
    Type: Application
    Filed: December 10, 2012
    Publication date: October 30, 2014
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
  • Patent number: 8637036
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: January 28, 2014
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Washington
    Inventors: John R. Mascola, Richard T. Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary J. Nabel, Peter D. Kwong, Tongqing Zhou, Mark Connors, William R. Schief
  • Publication number: 20130251726
    Abstract: The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.
    Type: Application
    Filed: March 10, 2013
    Publication date: September 26, 2013
    Applicants: International AIDS Vaccine Initiative, National Institutes of Health, The Scripps Research Institute
    Inventors: John Mascola, Dennis R. Burton, Wayne Koff, Peter Kwong, Gary Nabel, Sanjay K. Phogat, Pascal Raymond Georges Poignard, Melissa Danielle De Jean St. Marcel Simek-Lemos, Xueling Wu, Tongqing Zhou, Zhi-Yong Yang
  • Patent number: 8454972
    Abstract: The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: June 4, 2013
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, GenVec, Inc.
    Inventors: Gary J. Nabel, Ling Xu, Bimal Chakrabarti, Lan Wu, Zhi-yong Yang, Jason G. D. Gall, C. Richter King, Zengguang Wang
  • Patent number: 8323961
    Abstract: The invention provides a composition comprising four adenoviral vectors, each comprising a nucleic acid sequence encoding a clade A HIV Env protein, a clade B HIV Env protein, a clade C HIV Env protein, and a clade B HIV Gag-Pol fusion protein, respectively. The invention also provides a method of inducing an immune response against HIV-1 in an animal comprising administering the composition to the animal.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: December 4, 2012
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, GenVex, Inc.
    Inventors: Gary J. Nabel, Bimal Chakrabarti, Wing-Pui Kong, Yue Huang, Zengguang Wang, legal representative, Zhi-Yong Yang, Jason G. D. Gall, C. Richter King
  • Publication number: 20120282264
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
    Type: Application
    Filed: September 24, 2010
    Publication date: November 8, 2012
    Inventors: John R. Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Lawrence Shapiro, Jiang Zhu, William R. Schief
  • Publication number: 20120244166
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and uses of these antibodies, are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
    Type: Application
    Filed: March 23, 2012
    Publication date: September 27, 2012
    Inventors: John R. Mascola, Richard T. Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary J. Nabel, Peter D. Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Lawrence Shapiro, Jiang Zhu, William R. Schief
  • Publication number: 20120237523
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
    Type: Application
    Filed: March 23, 2012
    Publication date: September 20, 2012
    Inventors: John R. Mascola, Richard T. Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary J. Nabel, Peter D. Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Lawrence Shapiro, Jiang Zhu, William R. Schief
  • Publication number: 20120219584
    Abstract: Immunogens and compositions are provided that encode a protein comprising an influenza A subtype H1 hemagglutinin glycan-shielded receptor binding domain A (RBD A) region and at least one influenza A subtype H1 hemagglutinin antigenic site wherein the antigenic site is not within the RBD-A region. Also provided are immunogens and compositions that encode an immunogenic protein comprising at least one epitope of the RBD-A region of a pandemic influenza A subtype H1 hemagglutinin antigen. Also provided are such proteins, nucleic acids that encode such proteins, and antibodies against such proteins. Also provided are methods to use such immunogens and compositions to elicit a neutralizing antibody immune response against influenza A subtype H1 virus.
    Type: Application
    Filed: October 5, 2010
    Publication date: August 30, 2012
    Applicant: THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH
    Inventors: Gary J. Nabel, Chih-Jen Wei, Zhi-Yong Yang, Jeffrey Boyington
  • Publication number: 20120219583
    Abstract: The invention is directed to a nucleic acid molecule encoding a HIV-1 polypeptide which comprises the nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. The invention also provides a method of inducing an immune response against HIV-1 in a mammal.
    Type: Application
    Filed: October 15, 2010
    Publication date: August 30, 2012
    Applicants: Los Alamos National Security, LLC, The U.S. of America, as rep. by the Sec., Dept. of HHS
    Inventors: Gary J. Nabel, Zhi-Yong Yang, Wing-Pui Kong, Bette Korber